A Phase 1 Study of SAIL66 in Patients With CLDN6-positive Locally Advanced or Metastatic Solid Tumors

NCT05735366 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
22
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Chugai Pharmaceutical